A thought from my friend Carl:
MNOV is attempting to treat just about everything with its drugs. I have never seen any company of this size with so many irons in the fire. And they have been able to fund their trials with external sources of money.
MNOV's chart is improving. However it will take news that confirms that their drugs work in one of these research projects for a big move to take place. The market cap is about $97m so there is plenty of possible room to the upside if good news is revealed.
Kind regards,
Minding
-----------------
MediciNova initiates mid-stage study of MN-001 for elevated triglycerides in NASH patients
Nov 19 2015, 12:05 ET | By: Douglas W. House, SA News Editor Contact this editor with comments or a news tip
MediciNova (MNOV -1.9%) initiates a Phase 2a clinical trial assessing MN-001 (tipelukast) for the treatment of hypertriglyceridemia in NASH (nonalcoholic steatohepatitis) patients. The open-label, multicenter, proof-of-concept study will enroll ~20 participants. Eligible patients will have a confirmed diagnosis of NASH and serum triglyceride levels of at least 150 mg/dL (normal level is less than 150 mg/dL). Each subject will receive 250 mg of MN-001 once per day for four weeks followed by 250 mg twice per day for eight weeks.
MN-001 is under development for the treatment of NASH with fibrosis and ideopathic pulmonary fibrosis.
Tipelukast is a small molecule anti-fibrotic and anti-inflammatory compound that exerts its effects via several mechanisms, including leukotriene receptor antagonism and inhibiting enzymes known as phosphodiesterases as well as 5-lipoxygenase.
Previously: MediciNova's tipelukast Fast Track'd for ideopathic pulmonary fibrosis; shares up 17% premarket (Sept. 10)
Previously: MediciNova jumps on FDA OK of second Phase 2 protocol for MN-001 in NASH (July 27)
MediciNova Receives Notice of Allowance for New Patent Covering MN-221 (bedoradrine) for the Treatment of Irritable Bowel Syndrome in Japan
MNOV: Presentation on ALS Phase 2 Study in December?
FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of Idiopathic Pulmonary Fibrosis
MediciNova Announces First Advanced ALS Patient Using Non-Invasive Ventilation Support Enrolled in Phase 2 Clinical Trial of MN-166 (ibudilast)
MediciNova Announces the Completion of Enrollment in Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence
MediciNova Announces Randomization of 255 Subjects Completed in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS
FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of NASH with Fibrosis
AI
